DSTYK Inhibition Increases the Sensitivity of Lung Cancer Cells to T Cell–Mediated Cytotoxicity

Scientists identified DSTYK, a dual serine/threonine and tyrosine non-receptor protein kinase, as a novel actionable target altered in non-small cell lung cancer.